Stockrabit · Analysts
Questions across 24 calls

Sajal Kapoor

Antifragile Thinking

Concord Biotech Limited

Concord Biotech Limited CC-Jun26.pdf · 2026-06-01
I have three questions. First is, if FY26 was primarily a timing issue, which you have explained, right, rather than a demand issue, where should investors expect to see the release of that timing effect first? Will it be inventory or receivables or operating cash flow or revenue growth?
No, that's helpful, Ankur. I mean you mentioned that some of the tenders that couldn't land in FY26 are still work in progress, hopefully. So in that context, what percentage of current inventory is already linked to identified customer demand or customer forecast or commercial shipments that will start getting released from Q1 of this fiscal?

Blue Jet Healthcare Limited

Blue Jet Healthcare Limited CC-Jun26.pdf · 2026-05-25
I've only got 2 questions. First is are we at a stage where Blue Jet is deliberately optimizing more for future strategic positioning and embedded customer relevance rather than near -term operating efficiency?
That's helpful, VK. And second, with Mahad backward integration block expected to go live this fiscal, should we think of initial impact more through gross margin improvement and supply chain control with the top line benefits perhaps becoming visible only after customer validations and the scale up? Or how do you see that?

PI Industries Limited

PI Industries Limited CC-May26.pdf · 2026-05-20
Thank you for the opportunity. Two questions. PI has spent more than a decade discussing adjacencies like pharma, electronic chemicals, life sciences, yet agrochemicals still remain the dominant economic engine of the company and we have been discussing. So, as on today, from management’s perspective, was the original assumption that PI’s process chemistry and customer trust advantages w ould automatically transfer more easily across domains than they actually did? And what has been the biggest, unexpected challenge in building meaningful non-agro scale? That is my first question. Thank you.
Sure. That is helpful. I was actually alluding to the 2012 annual report, but anyway. I mean, what has PI learned so far about the difference between scaling Agchem CDMO versus scaling pharma CDMO and what capabilities still need to be built before PI can genuinely compete with established pharma synthesis leaders on innovation depth, not just chemistry execution. Thank you.

Neuland Laboratories Limited

Neuland Laboratories Limited CC-May26.pdf · 2026-05-12
Hi, team. It's always good to see the convex side of volatility and lumpiness, excellent show. I've got 2 questions. First is Neuland has built strong capabilities in complex chemistry and peptides, but the industry's value creation is in my view increasingly shifti ng towards hybrid modalities like ADCs and fermentation -enabled manufacturing. So what do you see as Neuland's biggest capability gap in sort of participating meaningfully in that kind of an ecosystem? And how are you addressing all of it today? That's my first question.
No, that's very thoughtful as always, Saharsh. Thank you for that. And second, a lot of newer enzymatic and bio -enabled manufacturing routes, they kind of look attractive at lab scale. But commercial manufacturing is ultimately constrained by yield consistency, purification economics, contamination controls and of course, the regulatory aspects are always there. So which of these do you believe is the biggest real bottleneck today? And where does advanced synthetic chemistry is still kind of retains a more durable economic advantage over these emerging biotech-led manufacturing routes?
Neuland Laboratories Limited CC-Feb26.pdf · 2026-02-09
Yes. Couple of questions from my side. So 1 of them is unit specific, but it's not for this quarter or this fiscal the question is, I mean, as Neuland shifted from low-margin APIs to complex APIs and CDMO services, and can you recall what were the hardest part of that transition that started somewhere around 2005 -2006. So ages ago, but what were the kind of hardest part of the transition that are perhaps not visible to a new investor or even your existing new employees who have joined recently?
Yes. No, that's helpful. I mean you guys kind of summarized the last 20 years of annual report and so to speak. And second question is I'm looking at Slide 12, and there is a kind of a pattern, and I saw you had joined the call late, so maybe I missed the initial 20 minutes. There is a pattern to my mind and help us just double-click on this one.? So, when I look at the development pipeline, right, from preclinical to Phase III, that's kind of consistently drying up or that's the impression I'm getting as an outsider. I mean if the development pipeline is not strong, how will the commercial pick up 3, 4, 5 years out? yes, you can always do a tech transfer, a molecule is shifting from China as an example? And that could be an inorganic addition, which is currently not in the dashboard. But looking at the organic pipeline, the development pipeline should pick up, right? I mean, otherwise, at some point in time, we may struggle with the commercial momentum. may not be immediately, but let's say, 3, 4, 5 years out?
Neuland Laboratories Limited CC-Nov25.pdf · 2025-11-07
Hi. Thanks for the opportunity and congratulations for maintaining a solid track record of volatility and lumpiness in performance. I have got two questions. First is, despite a noticeable slowdown in the CDMO development pipeline, Ne uland has added 25 new scientists. So, 360 to 385 is the new count. Could you explain the rationale behind increasing headcount when the development pipeline is at historic lows, if I look at the trend over the last four quarters? I am looking at the presentation.
Certainly. Now, that's helpful Saharsh. And my second and last question is, how does Ne uland ensure that its people strategy and governance framework stay aligned with the long -term innovation and sustainability goals while fostering empathy and ethical conduct under high performance pressure in the kind of R&D work that we do and the kind of scale -up chemistry that we undertake? Thanks.

Laurus Labs Limited

Analysts/Institutional Investor Meet/Con. Call Updates Laurus Labs Limited has informed the Exchange about Transcript · 2026-04-30
Yes. Dr. Satya, as we commission and scale the upcoming Vizag 400 KL fermentation, what could be the single biggest source of yield variability from things such as contamination, oxygen transfer, strain stability to even d ownstream recovery? And how tight do we expect the batch - to-batch variance when we actually commercialize that 400 KL capacity?
Right. Okay. So just a quick follow-up on that one. So clearly, we are moving into the world of material scien ces and biomaterials. I mean what does it mean for the steady -state economic model for Laurus, I mean, in terms of utilization, yields, pricing structure and customer concentration? And which of these kind of variables are most sensitive in achieving the aspirational return thresholds?
Laurus Labs Limited CC-May26.pdf · 2026-04-30
Yes. Dr. Satya, as we commission and scale the upcoming Vizag 400 KL fermentation, what could be the single biggest source of yield variability from things such as contamination, oxygen transfer, strain stability to even d ownstream recovery? And how tight do we expect the batch - to-batch variance when we actually commercialize that 400 KL capacity?
Right. Okay. So just a quick follow-up on that one. So clearly, we are moving into the world of material scien ces and biomaterials. I mean what does it mean for the steady -state economic model for Laurus, I mean, in terms of utilization, yields, pricing structure and customer concentration? And which of these kind of variables are most sensitive in achieving the aspirational return thresholds?
Analysts/Institutional Investor Meet/Con. Call Updates Laurus Labs Limited has informed the Exchange about Transcript · 2026-01-23
Thank you for taking my question and good afternoon, team. It's heartening to see a very strong jump in the operating cash flow. I am looking at the 9-month number. It's about 600% increase, but there is an interesting trend here Raviji, if you can elaborate and help us better understand this wider picture. So, if I look at the 10-year data, so I am looking at 2016 to 2025 cumulative, we clocked EBITDA of Rs. 8,500 crores and against that EBI TDA of Rs. 8,500 crores, we did an operating cash flow of about Rs. 5,400 crores so that's about 63% conversion. Whereas in the nine month, the conversion is 113%. So, 63% going to 70%-75% even 80% is understandable, there is a definite change in the net w orking capital strategy as far as I can understand. I f you could just help us double click and understand a more longer term and more sustainable conversion of EBITDA into operating cash flow? Thank you.
Sure, Raviji. Just to just to harp on that one, so given that the business characteristic is definitely changing in the favor of CDMO and this customer advances will be an ongoing thing, we cannot compare quarter-over-quarter for advances because in one year the advance may be higher than the other year, but on a broader 5-year basis for the going forward 5-years, I think the conversion should be a lot better than what we have delivered in the last 10 years. Is that a fair assumption?
Laurus Labs Limited CC-Jan26.pdf · 2026-01-23
Thank you for taking my question and good afternoon, team. It's heartening to see a very strong jump in the operating cash flow. I am looking at the 9-month number. It's about 600% increase, but there is an interesting trend here Raviji, if you can elaborate and help us better understand this wider picture. So, if I look at the 10-year data, so I am looking at 2016 to 2025 cumulative, we clocked EBITDA of Rs. 8,500 crores and against that EBI TDA of Rs. 8,500 crores, we did an operating cash flow of about Rs. 5,400 crores so that's about 63% conversion. Whereas in the nine month, the conversion is 113%. So, 63% going to 70%-75% even 80% is understandable, there is a definite change in the net w orking capital strategy as far as I can understand. I f you could just help us double click and understand a more longer term and more sustainable conversion of EBITDA into operating cash flow? Thank you.
Sure, Raviji. Just to just to harp on that one, so given that the business characteristic is definitely changing in the favor of CDMO and this customer advances will be an ongoing thing, we cannot compare quarter-over-quarter for advances because in one year the advance may be higher than the other year, but on a broader 5-year basis for the going forward 5-years, I think the conversion should be a lot better than what we have delivered in the last 10 years. Is that a fair assumption?
Analysts/Institutional Investor Meet/Con. Call Updates Laurus Labs Limited has informed the Exchange about Transcript · 2025-07-25
Yes. Dr. Satya, any progress update you can share regarding the Willow Bio and AI -driven bioengineering platform partnership we are progressing with? I mean what advantages does bioengineering provided over conventional che mical synthesis in terms of efficiency, cost and sustainability, please?
And do we expect the learnings out of this program to be kind of integrated into some of our future ventures? I mean because Bio is a very emerging promising area and we are just exploring the unhealthy tip of the iceberg.
Laurus Labs Limited CC-Jun25.pdf · 2025-07-25
Yes. Dr. Satya, any progress update you can share regarding the Willow Bio and AI -driven bioengineering platform partnership we are progressing with? I mean what advantages does bioengineering provided over conventional che mical synthesis in terms of efficiency, cost and sustainability, please?
And do we expect the learnings out of this program to be kind of integrated into some of our future ventures? I mean because Bio is a very emerging promising area and we are just exploring the unhealthy tip of the iceberg.

Granules India Limited

Granules India Limited CC-May26.pdf · 2026-04-29
Congratulations on an amazing execution despite the Gagillapur constraints. I have a few questions, please. What proportion of Granules' current and upcoming CDMO capacity is already tied to committed or late -stage customer programs? And what utilization level would you fall to if, let's say, a hypothetical scenario, your top 2 or top 3 projects were to be delayed or canceled?
No, that's helpful. So I think if I translate what you said, Sanjay, it's not speculative. It's tracking either a verbal commitment or tracking a late -stage plan program, so the capacities are not created for the heck of it. That's how I translate it. And if you could also clarify what is the level of customer concentration? I mean, typically, what happens is, at a low base -- and this has been the journey with Neuland Labs, Laurus Labs all of them. Typically, when your base is low, you are really dependent on just 1 or 2 customers. Are we also having that level of high dependency of customer concentration? Or are we having a broad-based participation, albeit -- despite having a very low base today?

Tata Elxsi Limited

Tata Elxsi Limited CC-Apr26.pdf · 2026-04-21
Yes, hi. Thanks for taking my questions. Sir, of the deals you have won recently, how much of the value is coming from existing customers expanding their engagements or wallet share versus entirely new logos, and how has this mix evolved over the last two or three years? That's my first question. Thank you.
Sure. And just to follow up, I mean, is there a pattern where the new logos typically take X number of years to scale up or is there no such pattern? I mean, it depends from customer to customer?

Gland Pharma Limited

Gland Pharma Limited CC-Feb26.pdf · 2026-01-28
Yes. Thank you for taking my questions. M r. Sadu, beyond the reported turnaround at Cenexi and congratulations by the way you have been sounding very positive over the previous few earnings call that this business will turn around. Now that the turnaround has happened? The question or the optics will now obviously shift to the EBITDA margin in the ROCE because it's relative to our base business, where we were before the acquisition, we were a lot higher on the EBITDA as well as the ROCE as those metrics have been diluted by Cenexi. So what is the steady state, maybe a midterm 3 -year kind of a road map to try and bridge the gap both on the ROCE as well as the EBITDA between our base business and Cenexi?
Sure. That's very helpful. And thank you for detailing the response, which kind of helps us better understand the overall synergies and the dynamics because you just absolutely, I agree that you can't look at the individual businesses as an individual part, you have to look at the whole. So I completely appreciate that. My second and last question is, regarding this biologic CDMO. So we are tripling the capacity, right, if I'm not mistaken, we are tripling the capacities from 8 KL to 23 KL, and what is the expected ROCE and this capacity expansion all backed by contracts GLAND] Gland Pharma LimitedJanuary 28, 2026reflect directly into Cenexi's business, but it also as a consol company, you should start lookingat it. I mean, if you look at this quarter itself, our milestone income in the U.S. actually has comedown drastically.But overall, it's only 2% decrease because most of the actually milestones also came from ourcontracts in Europe. So you should also see that how the Cenexi and Gland together helping thecompany which you talked about initially, but the focus was mostly on how to turn around. Butalso you should see in parallel, what are the synergies we can get out of this business, which willnot directly seen from Cenexi's business, but as a consol business what you can get out of this.So you will see the European business growing.And we also have to see 35% business is great, but also we have to see how dependent on — arewe on U.S. we have seen 2 years back when we had a setback, we are so dependent on U.S., wedecided, okay, we need to de-risk ourselves. So you should also look at now today, we aredependent on U.S. of 50% of business, 25% is in Europe.Now the quality of the business we do, we have to improve for sure. One is, of course, gettingthe efficiencies back. Second, how do we improve the portfolios of Cenexi. And that's the reasonwhy you see investments going into higher-end products, not just ampoule business, which isthere. And in pharma, it takes time. So it's the transition we are doing.And also, it has capabilities which Gland can exploit, whether it is herbal products, which wecan't make or the controlled substances, which we can't make. Now again, you have to look at itfrom a synergy perspective. So as Gland, you cannot do those kinds of products, with Cenexi,we can do the product. So in the future, you might see revenues coming out of Gland basebusiness, but it won't have happened if you don't have Cenexi.So as a company, I think we should start looking at how Cenexi contributed to Gland, how Glandis contributed to Cenexi rather than independently looking at Cenexi. Because that's how whenyou make an acquisition, we just don't look at single business. You see as a whole, how thebusiness works. And I think that's what we tend to tell that okay fine, we are turning it around.But how Cenexi is also contributing to us. So this is several our development projects.Now we have started R&D and so products where Gland cannot do it because of the facilitiesthat we don't have, where Cenexi has. So we start manufacturing from there. So I think from along-term strategic perspective, it's a move we consciously took. Yes, it took time of 2 years toget it turn around and this is our first acquisition. And we are integrating it. So you see morepositive results independently for Cenexi and also as a consol company.Sure. That's very helpful. And thank you for detailing the response, which kind of helps us betterunderstand the overall synergies and the dynamics because you just absolutely, I agree that youcan't look at the individual businesses as an individual part, you have to look at the whole. So Icompletely appreciate that. My second and last question is, regarding this biologic CDMO.So we are tripling the capacity, right, if I'm not mistaken, we are tripling the capacities from 8KL to 23 KL, and what is the expected ROCE and this capacity expansion all backed by contracts

Acutaas Chemicals Limited

Acutaas Chemicals Limited CC-Feb26.pdf · 2026-01-28
Fantastic work Acutaas team, moving -- not just looking at this quarter, I mean, moving gross margins from 40%, 45% to upwards of 55% now in just about 2 years is a clear testament to your focus on efficiency and smart execution. So well done on that. Coming to my questions, 3 years from now, what would convince us that Acutaas successfully transition from a diversified specialty chemicals company to a sort of scientifically differentiated electronics-grade chemicals platform? And what would failure look like 3 years out?
Yes. So in terms of some of the critical capabilities, I mean, be it talent, purity control, customer trust or capital, what out of these will be the hardest to scale? And how are you positioning yourself just to protect the downside?

Deepak Nitrite Limited

Deepak Nitrite Limited CC-Nov25.pdf · 2025-11-14
Maulik, I heard the refreshing keyword fungible earlier on the call. So how does the new state - of-the-art R&D center at Savli combined with Deepak's existing digital and intellectual capital, enable a more sort of nimble and multi -purpose incremental CAPEX investments approach, perhaps helping avoid the prolonged rigidity and risks that are often associated with large dedicated CAPEX in a volatile and uncertain world. That's my first question.
Yes. So data lake, I like that. And thanks for giving a very detailed and very reassuring answer. We have all been personally invested in Deepak for many, many years and look forward to a long-lasting glory ahead. My second question is, Maulik, given India currently imports all the polycarbonate, what market intelligence beyond "import substitution" underpins conviction in future domestic demands from EVs, electronics and also healthcare?

Aarti Industries Limited

Aarti Industries Limited CC-Nov25.pdf · 2025-11-07
Thank you for taking my question. First one is just an observation. The quality of communication and disclosures has improved significantly in recent quarters. So well done on that front. Even if you read through the annual report, the disclosures have significantly improved. That is one. And then we have stepped up our efforts in science and innovation, the intellectual property creation effort has increased. All that is good. The question I have is in an increasingly uncertain and random world, how do you see the balance sheet position? Would you be comfortable with the current debt profile we are carrying on the balance sheet? And what is the plan to sort of try and maybe deleverage amid the current wave of capex plus the fact that the next wave of capex will be much more focused on fungible, more science and innovation- led capex. So the capex is an ongoing effort. What I am sightly concerned about is the current debt levels that we have on our balance sheet.
That is helpful. That is all I wanted to check. Thank you.

Navin Fluorine International Limited

Navin Fluorine International Limited CC-Nov25.pdf · 2025-10-30
Sir, what concrete non-physical milestones things are such as master service agreements or co - development rights or intellectual property participation do you think define Navin Molecular progress towards becoming a more sort of integrated and strategic CD MO partner? So I'm looking for certain intangibles or nonfinancial parameters, if you can share.
So thank you for that. I mean that's the exact kind of detail I was seeking. My second and last question is, how are the digital manufacturing initiatives like the advanced process control systems, the real-time quality monitoring, all those digital initia tives, how are they translating into measurable margin improvement, yield enhancement or any sort of faster batch release within the CDMO business?